These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
318 related articles for article (PubMed ID: 15653175)
1. Immunochemical crossreactivity of antibodies specific for "advanced glycation endproducts" with "advanced lipoxidation endproducts". Richter T; Münch G; Lüth HJ; Arendt T; Kientsch-Engel R; Stahl P; Fengler D; Kuhla B Neurobiol Aging; 2005 Apr; 26(4):465-74. PubMed ID: 15653175 [TBL] [Abstract][Full Text] [Related]
2. Reaction of pyridoxamine with malondialdehyde: mechanism of inhibition of formation of advanced lipoxidation end-products. Kang Z; Li H; Li G; Yin D Amino Acids; 2006 Feb; 30(1):55-61. PubMed ID: 15990947 [TBL] [Abstract][Full Text] [Related]
3. Lipid peroxidation and advanced glycation end products in the brain in normal aging and in Alzheimer's disease. Dei R; Takeda A; Niwa H; Li M; Nakagomi Y; Watanabe M; Inagaki T; Washimi Y; Yasuda Y; Horie K; Miyata T; Sobue G Acta Neuropathol; 2002 Aug; 104(2):113-22. PubMed ID: 12111353 [TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus. Valente T; Gella A; Fernàndez-Busquets X; Unzeta M; Durany N Neurobiol Dis; 2010 Jan; 37(1):67-76. PubMed ID: 19778613 [TBL] [Abstract][Full Text] [Related]
5. Mass spectrometry to detect the site specificity of advanced glycation/lipoxidation end-product formation on protein: some challenges and solutions. Ames JM Biochem Soc Trans; 2008 Oct; 36(Pt 5):1051-4. PubMed ID: 18793187 [TBL] [Abstract][Full Text] [Related]
6. epsilon-Glycation, APP and Abeta in ageing and Alzheimer disease: a hypothesis. Schmitt HP Med Hypotheses; 2006; 66(5):898-906. PubMed ID: 16442744 [TBL] [Abstract][Full Text] [Related]
7. Maillard reaction products in tissue proteins: new products and new perspectives. Thorpe SR; Baynes JW Amino Acids; 2003 Dec; 25(3-4):275-81. PubMed ID: 14661090 [TBL] [Abstract][Full Text] [Related]
8. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Donahue JE; Flaherty SL; Johanson CE; Duncan JA; Silverberg GD; Miller MC; Tavares R; Yang W; Wu Q; Sabo E; Hovanesian V; Stopa EG Acta Neuropathol; 2006 Oct; 112(4):405-15. PubMed ID: 16865397 [TBL] [Abstract][Full Text] [Related]
9. Glutaraldehyde is an effective cross-linker for production of antibodies against advanced glycation end-products. Mera K; Nagai M; Brock JW; Fujiwara Y; Murata T; Maruyama T; Baynes JW; Otagiri M; Nagai R J Immunol Methods; 2008 May; 334(1-2):82-90. PubMed ID: 18353354 [TBL] [Abstract][Full Text] [Related]
10. Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer's disease. Yamagishi S; Nakamura K; Inoue H; Kikuchi S; Takeuchi M Med Hypotheses; 2005; 64(6):1205-7. PubMed ID: 15823718 [TBL] [Abstract][Full Text] [Related]
11. Characterization of anti-advanced glycation end product antibodies to nonenzymatically lysine-derived and arginine-derived glycated products. Choi YG; Lim S J Immunoassay Immunochem; 2009; 30(4):386-99. PubMed ID: 19739013 [TBL] [Abstract][Full Text] [Related]
12. Advanced glycation endproducts (AGE) on IgG, a target for circulating antibodies in North American Indians with rheumatoid arthritis (RA). Newkirk MM; LePage K; Niwa T; Rubin L Cell Mol Biol (Noisy-le-grand); 1998 Nov; 44(7):1129-38. PubMed ID: 9846895 [TBL] [Abstract][Full Text] [Related]
13. Usefulness of antibodies for evaluating the biological significance of AGEs. Nagai R; Fujiwara Y; Mera K; Motomura K; Iwao Y; Tsurushima K; Nagai M; Takeo K; Yoshitomi M; Otagiri M; Ikeda T Ann N Y Acad Sci; 2008 Apr; 1126():38-41. PubMed ID: 18079488 [TBL] [Abstract][Full Text] [Related]
14. Protein-bound advanced glycation endproducts (AGEs) as bioactive amino acid derivatives in foods. Henle T Amino Acids; 2005 Dec; 29(4):313-22. PubMed ID: 15997413 [TBL] [Abstract][Full Text] [Related]
15. Age- and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer's disease brains. Lüth HJ; Ogunlade V; Kuhla B; Kientsch-Engel R; Stahl P; Webster J; Arendt T; Münch G Cereb Cortex; 2005 Feb; 15(2):211-20. PubMed ID: 15238435 [TBL] [Abstract][Full Text] [Related]
16. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Vasan S; Zhang X; Zhang X; Kapurniotu A; Bernhagen J; Teichberg S; Basgen J; Wagle D; Shih D; Terlecky I; Bucala R; Cerami A; Egan J; Ulrich P Nature; 1996 Jul; 382(6588):275-8. PubMed ID: 8717046 [TBL] [Abstract][Full Text] [Related]
17. Advanced glycation endproducts in food and their effects on health. Poulsen MW; Hedegaard RV; Andersen JM; de Courten B; Bügel S; Nielsen J; Skibsted LH; Dragsted LO Food Chem Toxicol; 2013 Oct; 60():10-37. PubMed ID: 23867544 [TBL] [Abstract][Full Text] [Related]
18. Prevention of early renal disease, dyslipidaemia and lipid peroxidation in STZ-diabetic rats by LR-9 and LR-74, novel AGE inhibitors. Figarola JL; Scott S; Loera S; Xi B; Synold T; Weiss L; Rahbar S Diabetes Metab Res Rev; 2005; 21(6):533-44. PubMed ID: 15818713 [TBL] [Abstract][Full Text] [Related]
19. Protective role of antioxidative food factors in oxidative stress caused by hyperglycemia. Osawa T; Kato Y Ann N Y Acad Sci; 2005 Jun; 1043():440-51. PubMed ID: 16037265 [TBL] [Abstract][Full Text] [Related]
20. High dietary consumption of trans fatty acids decreases brain docosahexaenoic acid but does not alter amyloid-beta and tau pathologies in the 3xTg-AD model of Alzheimer's disease. Phivilay A; Julien C; Tremblay C; Berthiaume L; Julien P; Giguère Y; Calon F Neuroscience; 2009 Mar; 159(1):296-307. PubMed ID: 19135506 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]